Claims:

15

- 1. An isolated human epididymis-specific receptor protein-6 (HE6) polypeptide, comprising
- i) the amino acid sequence encoded by SEQ ID NO: 1;
- 5 ii) the amino acid sequence encoded by SEQ ID NO: 2;
 - iii) the amino acid sequence encoded by SEQ ID NO: 3;
 - iv) the amino acid sequence encoded by SEQ ID NO: 4;
 - v) the amino acid sequence encoded by SEQ ID NO: 5;
 - vi) the amino acid sequence encoded by SEQ ID NO: 6; or
- vii) the amino acid sequence encoded by SEQ ID NO: 7, or comprising a functional variant or functional fragment of an amino acid sequence of i) through vii).
 - 2. An isolated polypeptide that comprises an amino acid sequence which has a sequence identity of at least 65%, 70-75%, 80-85%, 90-95% or 97-99% to one or more of the amino acid sequences i) through vii) of claim 1.
 - 3. An isolated polypeptide of claim 1, which further comprises a heterologous sequence.
 - 4. An isolated polypeptide of claim 1, which comprises a polypeptide encoded by SEQ ID NO: 22 comprising the amino acid sequence as depicted in SEQ ID NO: 30.
- 5. An isolated polypeptide of claim 1, which comprises a polypeptide encoded by SEQ ID NO: 16-22, starting with AUG at nucleotide position 164-166 and terminating at stop codon at positions 3101-3103, 3143-3145, 3173-3175, 3167-3169, 3125-3127, or 3149-3151.
- 6. An isolated polypeptide encoded by SEQ ID NO: 16-22, starting at the codon at 2-4 and terminating at stop codon at positions 3101-3103, 3143-3145, 3173-3175, 3167-3169, 3125-3127, or 3149-3151.

PCT/EP2003/011662

- 7. An isolated polypeptide comprising, from N-terminus to C-terminus, the polypeptide sequence represented by amino acids 1 through 54 of SEQ ID NO: 22, covalently bound to the polypeptide X81892.
- 8. An isolated mouse epididymis-specific receptor protein-6 (ME6) polypeptide, comprising
 - i) the amino acid sequence encoded by SEQ ID NO: 9;
 - ii) the amino acid sequence encoded by SEQ ID NO: 10;
 - iii) the amino acid sequence encoded by SEQ ID NO: 11; or
- iv) the amino acid sequence encoded by SEQ ID NO: 12; or comprising a functional variant or functional fragment of an amino acid sequence of i) through iv).
- 9. An isolated polypeptide that comprises an amino acid sequence which has a sequence identity of at least 65%, 70-75%, 80-85%, 90-95% or 97-99% to one or more of the amino acid sequences i) through iv) of claim 8.
 - 10. An isolated polypeptide consisting essentially of amino acids 1 to 1009 of SEQ ID NO: 31.
 - 11. An isolated polypeptide of claim 8 which comprises amino acid sequences encoded by SEQ ID NO: 9, 10, 11, 12 or 13, and further comprises a heterologous sequence.
- 12. An isolated polypeptide of claim 8, which comprises a polypeptide encoded by SEQ ID NO: 23, 24, 25, or 26, starting with AUG at nucleotide position 72-74 and terminating at stop codons 3099-3101, 3051-3053, 3090-3092, and 3018-3020.
- 13. An isolated polypeptide of claim 8, which comprises the sequence beginning with amino acid 1 of the sequence represented by SEQ ID NO: 31.

15

- 14. An isolated rat epididymis-specific receptor protein-6 (RE6) polypeptide, comprising
- i) the amino acid sequence encoded by SEQ ID NO: 13;
- ii) the amino acid sequence encoded by SEQ ID NO: 14; or
- or comprising a functional variant or functional fragment of an amino acid sequence of i) through iii).
- 15. An isolated polypeptide that comprises an amino acid sequence which has a sequence identity of at least 65%, 70-75%, 80-85%, 90-95% or 97-99% to one or more of the amino acid sequences i) through iii) of claim 14.
 - 16. An isolated polypeptide of claim 14 which comprises amino acid sequences encoded by SEQ ID NO: 13, 14, or 15, and further comprises a heterologous sequence.
 - 17. An isolated polypeptide of claim 14, which comprises a polypeptide encoded by SEQ ID NO: 27, 28, or 29, starting with AUG at nucleotide position 60-62 and terminating at stop codons 3099-3101, and 3015-3017.
 - 18. An isolated polypeptide of claim 14, which comprises the sequence beginning with amino acid 1 of the sequence represented by SEQ ID NO: 32.
- 19. An isolated polynucleotide which encodes an HE6-polypeptide, or which encodes a functional variant or a functional fragment thereof, of claim 1.
 - 20. An isolated polynucleotide which comprises the nucleotide sequence of
 - i) SEQ ID NO: 1,
 - ii) SEQ ID NO: 2,
- 30 iii) SEQ ID NO: 3,
 - iv) SEQ ID NO: 4,
 - v) SEQ ID NO: 5,
 - vi) SEQ ID NO: 6, or

- vii) SEQ ID NO: 7, or a functional fragment or variant thereof, provided that said fragment
- comprises either SQ ID NO: 1, 2, 3, 4, 5, 6, or 7.
- 5 21. An isolated polynucleotide which comprises the nucleotide sequence of
 - i) SEQ ID NO: 9
 - ii) SEQ ID NO: 10,
 - iii) SEQ ID NO: 11, or
 - iv) SEQ ID NO: 12
- or a functional fragment or variant thereof, provided that said fragment comprises either SQ ID NO: 9, 10, 11, or 12.
 - 22. An isolated polynucleotide which comprises the nucleotide sequence of
 - i) SEQ ID NO: 13,
- 15 ii) SEQ ID NO: 14, or

- iii) SEQ ID NO: 15
- or a functional fragment or variant thereof, provided that said fragment comprises either SQ ID NO: 13, 14, or 15.
- 23. Isolated polynucleotides of claim 20, 21, 22 which further comprise heterologous sequences.
 - 24. An isolated polynucleotide comprising from the 5' to the 3' terminus, an oligonucleotide consisting essentially of nucleotides 1-91 of SEQ ID NO: 16 covalently bound, in phase, to the polynucleotide X81892.
 - 25. An isolated polynucleotide of claim 20, which comprises SEQ ID NOS:16, 17, 18, 19, 20, 21 or 22.
- 26. An isolated polynucleotide of claim 21, which comprises SEQ ID NOS: 23, 24, 25, or 26.

WO 2004/037860 PCT/EP2003/011662

-54-

- 27. An isolated polynucleotide of claim 22, which comprises SEQ ID NOS:27, 28, or 29.
- 28. An isolated polynucleotide which comprises a nucleotide sequence that codes without interruption for the polypeptide of SEQ ID NO: 30, or which comprises a nucleotide sequence that codes without interruption for a fragment or variant of the polypeptide of SEQ ID NO: 30, or a complement thereof.
- 29. Recombinant constructs comprising the polynucleotides of claim 20, 21, 22 operatively linked to a regulatory sequence.
 - 30. A cell comprising a polynucleotide of claim 20 which expresses an HE-6 polypeptide.
- 31. A cell comprising a polynucleotide of claim 21 which expresses an ME-6 polypeptide.

20

- 32. A cell comprising a polynucleotide of claim 22 which expresses an RE-6 polypeptide.
- 33. A method of making epididymis-specific receptor-6 polypeptides, or functional fragments or variants thereof, comprising incubating a cell of claim 35-37 under conditions which allow expression of said polypeptides, fragments or variants, and recovering the polypeptides, fragments or variants.
- 34. An antibody or antigen-specific fragment specific for a polypeptide comprising amino acid sequences of claims.1, 8, and 14.
- 35. An antibody according to claim 34, wherein said antibody is a monoclonal antibody.
 - 36. A pharmaceutical composition comprising an antagonist or inhibitor of a polypeptide comprising amino acid sequences encoded by SEQ ID NO: 1, 2, 3,

WO 2004/037860 PCT/EP2003/011662

-55-

- 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, or 22 and a pharmaceutically acceptable carrier.
- 37. A pharmaceutical composition comprising an antisense nucleotide which can bind with any of the nucleotide sequences shown in SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, or 22 and a pharmaceutically acceptable carrier.
- 38. A pharmaceutical composition comprising an antibody of claim 34 and 35 and a pharmaceutically acceptable carrier.

15

20

25

- 39. A pharmaceutical composition for treating a male reproductive disorder comprising administering an effective amount of a polypeptide comprising amino acid sequences encoded by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, o r 22.
- 40. A pharmaceutical composition for diagnosing a male reproductive disorder comprising administering an effective amount of a polypeptide comprising amino acid sequences encoded by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 12, 13, 14, 15, 27, 28, or 29.
- 41. A method of isolating an agent which modulates expression activity of an epididymis-specific receptor of claim 1, 8, or 14, or of a polynucleotide which encodes it, comprising incubating said epididymis-specific receptor or polynucleotide with a putative agent, and measuring the amount of activity of said receptor or polynucleotide.
- 42. The method of claim 41 wherein said agent is an antisense oligonucleotide according to claim 37.
- 43. The method of claim 41 wherein said agent is a ligand of said receptor.

44. A method for isolating a ligand specific for an epididymis-specific receptor of claim 1, 9, or 14, comprising contacting the epididymis-specific receptor with a substance suspected to be a ligand of said receptor and detecting binding of said receptor to said ligand.

45. The method of claim 41-44, wherein the said agent or ligand is an agonist of the epididymis-specific receptor.

46. The method of claim 41-44, wherein the said agent or ligand is an antagonist of the epididymis-specific receptor.

5

20

- 47. The method of claim 41-44, wherein the said agent or ligand is an antibody or polypeptide.
- 15 48. The method of claim 41-44, wherein the said agent or ligand is a small molecule which binds to the epididymis-specific receptor.
 - 49. A method for diagnosing infertility in a male mammal, which is associated with under-expression or over-expression of a polynucleotide comprising a sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, or 22, comprising contacting a tissue, cell, or polynucleotide from said male with a probe that is specific for said SEQ ID and determining the amount of nucleic acid that hybridizes to the probe wherein said cell or tissue is from a biopsy sample or thin section from the epididymis of said male mammal.
 - 50. A method for diagnosing infertility in a male mammal comprising measuring antibodies from said male specific for a polypeptide comprising a sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21 or 22.
- 51. A method for treating infertility in a male mammal comprising administering to said mammal an agonist or antagonist of an epididymis-specific receptor comprising administering an effective amount of a polypeptide comprising amino

acid sequence encoded by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21 or 22.

- 52. A method for contraception in a male mammal comprising administering to said mammal an antagonist of an epididymis-specific receptor comprising a polypeptide encoded by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21 or 22.
- 53. A recombinant construct comprising the polynucleotide of SEQ ID NO:33 operatively linked to a regulatory sequence.
 - 54. An antibody or an antigen-specific fragment specific for human HE6 polypeptide comprising amino acid sequences encoded by SEQ ID NO:33.
- 55. A pharmaceutical composition comprising an antagonist or inhibitor of a polypeptide comprising amino acid sequences encoded by SEQ ID NOS: 34 or 35.
- 56. A pharmaceutical composition for treating a male reproductive disorder comprising administering an effective amount of a polypeptide comprising an amino acid sequence encoded by SEQ ID NO:33.
 - 57. A composition for diagnosing a male reproductive disorder comprising administering an effective amount of a polypeptide comprising amino acid sequences encoded by SEQ ID NO:33.
 - 58. Isolated proteins encoded by DNA of any of the claims 25, 26, 27, comprising the amino acid sequences of SEQ ID NO 36-60.